Fujian Cosunter Pharmaceutical Cries Eureka in Joint Development of Liver Cancer Drug
Dou Shicong
/SOURCE :
Fujian Cosunter Pharmaceutical Cries Eureka in Joint Development of Liver Cancer Drug

(Yicai Global) Sept. 26 -- A breakthrough has come in the new hepatocellular carcinoma targeting drug Fujian Cosunter Pharmaceutical [SHE:300436] and WuXi AppTec Co. have jointly developed.

 The new drug, coded GST-HG161, possesses such virtues as great efficacy, good target selectivity and high safety, and its targeted therapy is effective for more than 30% of liver cancer patients, yesterday's filing by Fujian Cosunter Pharmaceutical shows.

 Founded in 2000, WuXi AppTec is a world-leading pharmaceutical, biotechnology and medical device research and development company. It has 16,000 employees and its research and development bases and production plants cover an area of 600,000 square meters, information on its official website shows.

 Liver cancer has the third highest incidence and the second highest mortality rate among malignant tumors in China, whose patients make up 54% of the world's total, as 370,000 Chinese people die of liver cancer each year. The only domestic targeted drug for its treatment -- sorafenib -- is of limited effect in prolonging longevity, has a low effective percentage among patients and exhibits clear side effects.

 GST-HG161 is set for concurrent submission of clinical research applications to China's Food and Drug Administration and US Food and Drug Administration in next year's first half.

Follow Yicai Global on